Kangle Pharmaceutical

Chongqing Kangle Pharmaceutical Co., Ltd., founded in 1988, is located in the *Chemical Industry Park (No. 4 Huazhong Avenue, Changshou Chemical Industry Park, Chongqing Municipality). It is affiliated with Tsinghua Tongfang Pharmaceutical Group Co., Ltd. and is the only API and pharmaceutical intermediate production base focusing on chemical synthesis under Tongfang Pharmaceutical Group, integrating R&D, production, and sales as a high-tech enterprise. Kangle Company has established an Academician and Expert Workstation with Tsinghua University and is a teaching and internship base of Tsinghua University; it has been awarded the title of Municipal-level "Technology R&D Center" of Chongqing. The company's quality system complies with ICH requirements and has passed multiple certifications including GMP certification of the National Medical Products Administration, U.S. FDA certification, and Japanese GMP certification. Guided by the market and centered on quality management, the company's products are listed in the China High-Tech Product Catalog, with over 80% of products for export.
The company is an enterprise in a *chemical industry professional park, with a superior geographical location and convenient transportation. It is located at the Yanjia exit of the Yuchang Expressway, 60 km from Chongqing Jiangbei International Airport, 60 km from the city center, 2 km from Changshou Railway Station, and 1 km from the Yangtze River wharf.
The company plans to cover an area of 136 mu, with 44 mu already built and 92 mu in Phase III under construction. It currently has more than 260 employees, 25% of whom are professional technical personnel; among them, 7 hold master's degrees and 50 hold bachelor's degrees. The plant facilities meet GMP requirements, and the company has a sound organizational structure with fifteen departments. It possesses modern production lines designed according to GMP requirements and an advanced quality inspection and analysis laboratory, making it a pharmaceutical high-tech enterprise integrating R&D, production, and sales. The company has obtained 6 key new products, 2 Chongqing municipal technological innovation projects, and 6 science and technology plan projects of Changshou District. The company owns 151 patents, including 91 invention patents. The company has been successively rated as a "Chongqing Key Supported Small and Medium-sized Enterprise," a demonstrative production enterprise, an enterprise with outstanding innovation work, a National High-tech Enterprise, a National Intellectual Property Advantage Enterprise, and has been awarded the title of Municipal-level "Technology R&D Center" of Chongqing. After the outbreak of the COVID-19 pandemic in 2020, upon receiving a notice from the Ministry of Industry and Information Technology of China to resume production of chloroquine phosphate as soon as possible, our company urgently launched the production of chloroquine phosphate, supplying about 95% of China's domestic demand for chloroquine phosphate API, making a significant contribution to China's victory in the fight against the pandemic, and was praised by the Medical Materials Support Group of the State Council's Response to the COVID-19 Pandemic as a "factory worthy of the name in fighting the pandemic."
The company's main products include: tigecycline, hydroxychloroquine sulfate, piperaquine phosphate, amodiaquine hydrochloride, chloroquine phosphate, chloroquine sulfate, cilostazol, 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole, benzhydrylthioacetamide, 4,7-dichloroquinoline, and key intermediates of rocuronium bromide, etc. The company's products are mainly for export, sold to Europe, America, Southeast Asia, Africa, and other places; at the same time, they sell well in major domestic pharmaceutical markets and pharmaceutical foreign trade companies. Among them, cilostazol, benzhydrylthioacetamide, and the key intermediate of rocuronium bromide have been rated as municipal key new products by the Chongqing Science and Technology Commission; chloroquine phosphate is also used as an API for treating COVID-19.
The company provides paid annual leave, holiday consolation money, birthday gift money, year-end consolation money; free working meals, accommodation, commuter shuttle buses, health examinations, and enrollment in mutual aid associations, etc.
The company has always attached importance to talent cultivation and the improvement of employees' professional quality. It holds various on-the-job training sessions each year totaling 100 class hours per person, and at the same time selects outstanding employees for further study outside the company, providing good opportunities and a larger platform for each employee's career development.